These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 29251327

  • 21. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
    Honma Y, Shimizu S, Takehara T, Harada M.
    J Gastroenterol; 2014 Mar; 49(3):517-26. PubMed ID: 23543326
    [Abstract] [Full Text] [Related]

  • 22. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF, Ding J, Zhang RG, Ren JH, Ma CM, Wu G.
    Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    D'Alessandro R, Refolo MG, Lippolis C, Carella N, Messa C, Cavallini A, Carr BI.
    Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
    [Abstract] [Full Text] [Related]

  • 26. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J, Zhai B, Sun W, Hu F, Cheng H, Xu J.
    PLoS One; 2017 Jun; 12(9):e0185088. PubMed ID: 28934275
    [Abstract] [Full Text] [Related]

  • 27. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
    Fritsche-Guenther R, Witzel F, Kempa S, Brummer T, Sers C, Blüthgen N.
    Oncotarget; 2016 Feb 16; 7(7):7960-9. PubMed ID: 26799289
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.
    Carr BI, Wang Z, Wang M, Cavallini A, D'Alessandro R, Refolo MG.
    Cancer Biol Ther; 2011 Sep 15; 12(6):531-8. PubMed ID: 21734462
    [Abstract] [Full Text] [Related]

  • 30. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N, Streit S, Wybranski C, Jürgens J, Brauner J, Schulz N, Powerski M, Ricke J, Kalinski T, Dudeck O, Seidensticker M.
    Anticancer Res; 2017 Jan 15; 37(1):87-93. PubMed ID: 28011478
    [Abstract] [Full Text] [Related]

  • 31. NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.
    Yu P, Ye L, Wang H, Du G, Zhang J, Zhang J, Tian J.
    Tumour Biol; 2015 Mar 15; 36(3):2143-53. PubMed ID: 25398692
    [Abstract] [Full Text] [Related]

  • 32. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X.
    Mol Oncol; 2017 Mar 15; 11(3):320-334. PubMed ID: 28164434
    [Abstract] [Full Text] [Related]

  • 33. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
    Kim JS, Choi GH, Jung Y, Kim KM, Jang SJ, Yu ES, Lee HC.
    J Cancer Res Clin Oncol; 2018 Aug 15; 144(8):1487-1501. PubMed ID: 29858683
    [Abstract] [Full Text] [Related]

  • 34. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY, Askarian-Amiri M, Finlay GJ, Rewcastle GW, Baguley BC.
    PLoS One; 2015 Aug 15; 10(7):e0131400. PubMed ID: 26148118
    [Abstract] [Full Text] [Related]

  • 35. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E.
    Cancer Chemother Pharmacol; 2013 May 15; 71(5):1297-307. PubMed ID: 23479136
    [Abstract] [Full Text] [Related]

  • 36. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
    Hu YT, Shu ZY, Jiang JH, Xie QF, Zheng SS.
    Hepatobiliary Pancreat Dis Int; 2020 Dec 15; 19(6):547-554. PubMed ID: 33051131
    [Abstract] [Full Text] [Related]

  • 37. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N.
    Int J Cancer; 2012 Aug 01; 131(3):548-57. PubMed ID: 21858812
    [Abstract] [Full Text] [Related]

  • 38. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
    Tan W, Zhu S, Cao J, Zhang L, Li W, Liu K, Zhong J, Shang C, Chen Y.
    Oncol Res; 2017 Nov 02; 25(9):1543-1553. PubMed ID: 28276313
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.